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Abstract. 
 
To investigate the expression and biological
roles of cytokeratin 19 (K19) in development and in
 
adult tissues, we inactivated the mouse K19 gene (
 
Krt1-
 
19
 
) by inserting a bacterial 
 
b
 
-galactosidase gene (
 
lacZ
 
)
by homologous recombination in embryonic stem cells,
and established germ line mutant mice. Both heterozy-
gous and homozygous mutant mice were viable, fertile,
and appeared normal. By 7.5–8.0 days post coitum
(dpc), heterozygous mutant embryos expressed 
 
lacZ
 
 in
the notochordal plate and hindgut diverticulum, reﬂect-
ing the fact that the notochord and the gut endoderm
are derived from the axial mesoderm-originated cells.
In the adult mutant, 
 
lacZ
 
 was expressed mainly in epi-
thelial tissues. To investigate the possible functional co-
operation and synergy between K19 and K8, we then
constructed compound homozygous mutants, whose
 
embryos died 
 
z
 
10 dpc. The lethality resulted from de-
fects in the placenta where both K19 and K8 are nor-
 
mally expressed. As early as 9.5 dpc, the compound
mutant placenta had an excessive number of giant tro-
phoblasts, but lacked proper labyrinthine trophoblast
or spongiotrophoblast development, which apparently
caused ﬂooding of the maternal blood into the embry-
onic placenta. These results indicate that K19 and K8
cooperate in ensuring the normal development of pla-
cental tissues.
Key words: embryo • endoderm • epithelium • kera-
tin • trophoblasts
 
Introduction
 
Cytokeratin-intermediate filaments are encoded by a mul-
tigene family of 
 
z
 
20 related polypeptides. They are ex-
pressed mainly in epithelial cells depending on the extent
of differentiation (Moll et al., 1982). Cytokeratin proteins
are classified into two types: smaller and acidic type I, and
larger and more basic type II (Steinert and Roop, 1988). In
simple epithelia, they form cytokeratin filaments through
obligate heteropolymerization of the type I and type II
proteins in particular combinations. For example, cytoker-
atin 8 (K8)
 
1
 
 and cytokeratin 18 (K18); K8, K18, and K19;
or cytokeratin 7 (K7), K8, K18 and K19 (Moll et al., 1982;
Lane et al., 1983; Sun et al., 1984; Quinlan et al., 1985).
The smallest type I cytokeratin, K19 (Mr; 40 kD) was first
recognized as a distinct form in squamous cell carcinoma
lines (Wu and Rheinwald, 1981). Cytokeratins share a
common structural organization: a central 
 
a
 
-helical rod
domain flanked by head and tail domains. Although K19
has a highly conserved central 
 
a
 
-helical rod essential for
filament formation (Steinert and Roop, 1988) and the
head domain, it is distinguished from other cytokeratins by
lacking a tail domain (Bader et al., 1986; Ichinose et al.,
1989; Lussier et al., 1989; Stasiak et al., 1989). The gene en-
coding mouse K19 (
 
Krt1-19
 
) is located on chromosome 11,
in the immediate neighborhood of the K15 gene (
 
Krt1-15
 
)
 
,
 
separated by only 4 kb (Lussier et al., 1990; Nozaki et al.,
1994). The human K19 gene (
 
KRT19
 
) is located on chro-
mosome 17 (Bader et al., 1988). While K19 and K15 are
coexpressed in certain cell types, they are not in others
(Ichinose et al., 1989; Nozaki et al., 1994). K19 is one of
the most representative proteins of epithelial cells such as
those in the intestine, kidney collecting ducts, gallbladder,
mesothelium, and secretory glands (Moll et al., 1982; Sun
et al., 1984; Quinlan et al., 1985; Bosch et al., 1988). In the
mouse blastocyst trophectoderm, K19 is induced after K8
and K18 upon implantation (Jackson et al., 1980; Nozaki
et al., 1988; Takemoto et al., 1991; Tamai et al., 1991). In
the mouse embryo proper, K19 mRNA becomes detect-
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able by 9.5 days post coitum (dpc) (Lussier et al., 1989),
and is probably expressed earlier (Jackson et al., 1981;
Franke et al., 1982). Differentially expressed individual cy-
tokeratins, including K19, are remarkably stable markers
in various types of carcinomas even when other markers
have been lost (Kasper et al., 1987; Pujol et al., 1993; Moll,
1994). Accordingly, cytokeratins are used for carcinoma
subtyping regarding the extent of differentiation and their
origins, especially for metastatic foci. Progress has been
made in understanding the functions of cytokeratins in the
skin. Point mutations in cytokeratin genes (Fuchs, 1994;
McLean and Lane, 1995) and transgenic (Vassar et al.,
1991) or knockout mice have indicated a structural func-
tion for epidermal keratins (for a review, see Magin, 1997).
Homozygous mutant embryos for the simple epithelia
type K8 gene (
 
Krt2-8
 
) are retarded in growth and suffer
from internal bleeding, with an abnormal accumulation of
erythrocytes in the fetal liver (Baribault et al., 1993, 1994).
These alterations are consistent with a placental or ex-
traembryonic deficiency. While this mutation shows a 94%
penetrance in the C57BL/6 background, the proportion of
viable homozygotes increases in the FVB/N background,
and colorectal hyperplasia and inflammation are observed
in adults that escape embryonic lethality. Recently, K8
and K18 have been shown to confer resistance to tumor
necrosis factor–induced apoptosis (Caulin et al., 2000).
Based on its structure and tissue distribution, K19 has
been suggested to counterbalance type II keratins (Ecker,
1988; Stasiak et al., 1989). To determine the expression
pattern and function of K19, we have constructed a 
 
Krt1-
19
 
 null mutant allele by knocking in a 
 
lacZ
 
 cassette at the
translation initiation site. We also generated compound
homozygotes of 
 
Krt1-19
 
 and 
 
Krt2-8
 
 mutations and found
that homozygous embryos are not viable due to defective
placental tissues, a phenotype not observed in the simple
homozygous mutants.
 
Materials and Methods
 
Construction of a Krt1-19 Targeting Vector
 
A 
 
l
 
 recombinant clone containing the mouse 
 
Krt1-19
 
 was isolated from a
129/Sv genomic library using a 1.4-kb full-length K19 cDNA fragment as a
probe as previously characterized (Ichinose et al., 1989; Nozaki et al.,
1994). A 6.5-kb SalI–KpnI fragment containing a part of exon 1 and a 641-
bp KpnI–BglII fragment downstream from a KpnI site in exon 1 were ex-
cised from this recombinant phage and subcloned in the pUC19 vector.
The ATG translation initiation codon in exon 1 was converted to a KpnI
site. A 365-bp KpnI fragment in exon 1 was replaced with a cassette con-
taining a 
 
lacZ
 
 reporter and PGKneobpA (Soriano et al., 1991). Thus, the
targeting vector pJBX carried a long homology arm of 6.1 kb.
 
Transfection of Embryonic Stem Cells and Selection 
of Targeted Clones
 
D3a2 embryonic stem (ES) cells (Shull et al., 1992) were cultured on neo-
mycin-resistant (neo
 
r
 
) mouse embryonic fibroblasts (Oshima et al., 1995).
50 
 
m
 
g of the targeting vector were linearized at the unique Sse8387I site
and electroporated into 10
 
7
 
 ES cells at 250 V and 500 
 
m
 
F. 24 h later, 150
 
m
 
g/ml (titer) of G418 (Geneticin; Sigma-Aldrich) was added. 7 d later, sin-
gle colonies were isolated and cultured in duplicate. G418-resistant colo-
nies were screened for homologous recombination by PCR using oligonu-
cleotide primers: one complementary to neo
 
r
 
; PGK
 
r
 
 (5
 
9
 
-CTA AAG CGC
ATG CTC CAG ACT-3
 
9
 
) and the other located 92-bp downstream from
the 3
 
9
 
 BglII site in 
 
Krt1-19
 
; K19-R2G (5
 
9
 
-AAG AGC TCC CTG ACT
AGA TTC AAG TTA ACT-3
 
9
 
). 35 cycles of amplification were per-
formed (denaturation, 1 min at 94
 
8
 
C; hybridization, 2 min at 60
 
8
 
C; and
elongation, 2 min at 72
 
8
 
C) in 50 
 
m
 
l reaction mixtures containing 50 pmol
 
of each oligonucleotide, 1 U Taq polymerase (TAKARA), 0.5 U Perfect
Match
 
®
 
 (Stratagene), and 1 
 
m
 
l of the crude cell lysate in each mixture. As
shown in Fig. 1 (below), only homologous recombinants showed a 739-bp
band. Candidates for homologous recombinants were expanded and veri-
fied by Southern hybridization with probes either internal (a 630-bp PstI–
XbaI fragment containing the neo
 
r
 
 segment of pPGKneobpA) or external
(a 556-bp fragment located downstream from the 3
 
9
 
 BglII site) to the tar-
geting vector sequence.
 
Generation and Genotyping of the Mutant Mice
 
Chimeras were generated by injection of the ES cells into C57BL/6 (B6)
blastocysts, followed by transfers to MCH (CLEA) foster mothers. Chi-
meric mice were backcrossed to B6 mice, and germ line transmission was
determined by the presence of the agouti coat color. Heterozygous off-
springs were identified by PCR and Southern analysis of tail DNA sam-
ples. Tail tips were incubated in lysis buffer of SepaGene
 
®
 
 (Sankojun-
yaku), in the presence of 1 mg/ml proteinase K overnight at 55
 
8
 
C. DNA
was extracted according to the manufacturer’s protocol. The wild-type al-
lele was identified using two primers sandwiching the deleted portion of
exon 1 (sense primer, endo-F: 5
 
9
 
-CCT GAC TAG ATT CAA GTT AAC
TG-3
 
9
 
,
 
 
 
and antisense primer, endo-R: 5
 
9
 
-TGG CGG AGT CCG CGG
TGG AAG TT-3
 
9
 
). 35 cycles (denaturation, 1 min at 94
 
8
 
C; annealing, 2
min at 60
 
8
 
C; and elongation, 2 min at 72
 
8
 
C) were performed to amplify the
958-bp fragment. The 
 
Krt2-8
 
 alleles were identified as described before
(Baribault et al., 1994).
 
Histochemical Localization of the
 
b
 
-Galactosidase Activity
 
For the timing of embryos, the morning of the vaginal plug was considered
as 0.5 dpc. When removed from the decidua, embryos were staged accord-
ing to Kaufman (1992) and genotyped as described above using DNA ex-
tracted from the yolk sac or from the embryo itself. To detect the 
 
b
 
-galac-
tosidase activity, the samples were incubated at 30
 
8
 
C for 30 min to 3 h,
depending on their sizes in a staining solution (5 mM potassium ferricya-
nide, 5 mM potassium ferrocyanide, 1 mg/ml X-gal in PBS). For paraffin
sectioning, samples were fixed in 4% paraformaldehyde according to the
standard procedures.
 
Immunohistochemistry
 
For immunofluorescence staining, tissues were fixed in 100% methanol at
4
 
8
 
C for 10 min, rinsed in PBS, and embedded in the O.C.T. compound.
The frozen sections were prepared at 20-
 
m
 
m thickness, followed by incu-
bation in 0.3% H
 
2
 
O
 
2
 
/PBS for 30 min at room temperature. Sections of em-
bryos and adult tissues were incubated with a blocking solution (3% BSA,
5% goat serum, and 0.2% Triton X-100 in PBS) for 1 h at room tempera-
ture. The primary antibodies TROMA-1, -2, and -3 raised against K8, K18,
and K19, respectively, were obtained from Dr. Kemler (Max-Planck Insti-
tute of Immunology, Freiburg, Germany; Kemler et al., 1981; Boller et al.,
1987), and were used at a dilution of 1:10 and incubated with the speci-
mens for 1 h at room temperature. Antibodies against K7 and Kip2 were
purchased from Euro-Diagnostica and Santa Cruz Biotechnology, Inc., re-
spectively. Sections were washed, and then incubated with FITC-conju-
gated secondary antibodies (Amersham, UK). For peroxidase-coupled re-
actions, tissues were fixed in 4% paraformaldehyde or 70% ethanol and
embedded in paraffin. Sections were incubated with peroxidase-conju-
gated secondary antibodies (Amersham Pharmacia Biotech) using a sub-
strate kit (Vector Laboratories) according to the manufacturer’s protocol.
 
In Situ Hybridization of Whole Mount Embryos
 
Whole mount in situ hybridizations of the 9.0–9.5-dpc embryos were car-
ried out as described previously (Saga et al., 1996) using digoxigenin-
UTP–labeled single-strand RNA probe. The K19 probe was transcribed
from a K19 cDNA fragment (Ichinose et al., 1989).
 
Results
 
Disruption of the Mouse K19 Gene (Krt1-19) by 
Homologous Recombination in ES Cells
 
To construct 
 
Krt1-19
 
 knock out mice, one of the 
 
Krt1-19
 
 al-
leles was inactivated by homologous recombination in ES 
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cells. The translation initiation site of 
 
Krt1-19
 
 was disrupted
so that a bacterial 
 
lacZ
 
 gene was placed under the control of
the 
 
Krt1-19 
 
promoter (Fig. 1 a). 200 G418-resistant clones
were analyzed, and three independent homologous recom-
binant candidates were isolated. Homologous recombina-
tion in these ES clones were verified further by PCR and
Southern analyses (Fig. 1 b). All three recombinant ES lines
were injected into C57BL/6 (B6) blastocysts and two germ
line chimeras were generated. About half of their agouti
offspring carried the knockout allele. The heterozygous
mutant mice were viable, fertile, and appeared normal.
Upon intercrosses of heterozygous mutants, the distri-
bution of the wild type (
 
1
 
/
 
1
 
), heterozygous (
 
1
 
/
 
2
 
), and
homozygous (
 
2
 
/
 
2
 
) mice were not significantly different
from the expected Mendelian ratio in the F
 
1
 
 and B6 back-
cross mice (Table I). In the FBV/N backcross offspring,
however, the homozygote numbers were smaller than ex-
pected (
 
P
 
 < 0.05). While the reason for this phenomenon
remains to be investigated, the FVB/N K19 mutant was
maintained thereafter as homozygotes because they sur-
vived and reproduced without affecting the litter size or
the sex ratio (data not shown). The homozygous 
 
Krt1-19
 
mutants did not show any particular phenotypic changes,
and appeared identical to their heterozygous and wild-
type littermates in their gross anatomy, histology, and be-
havior. Up to the age of 20 mo, we have not observed any
difference in changes associated with aging.
To investigate K19 expression in the mutant mice, RNA
samples from the small intestine and colon of the homozy-
gous, heterozygous, and wild-type mice were analyzed by
Northern hybridization (Fig. 1 c). The knockout mutation
Figure 1. Inactivation of the mouse K19 gene (Krt1-19) by homol-
ogous recombination. (a) Structures of the wild-type allele, target-
ing vector pJBX, and the targeted allele. The targeting vector con-
tained two regions of homology to the genomic DNA, sandwiching
a  lacZ reporter-neo selection cassette. Homologous recombina-
tion resulted in deletion of most of exon 1, and the lacZ reporter
was transcribed from the Krt1-19 promoter. Filled boxes represent
exons; noncoding regions are shown as solid lines. Arrowheads in-
dicate the positions of the PCR primers for genotyping: KO PCR,
primers for the targeted allele, and WT PCR, primers for the wild-
type allele. The probe for Southern hybridization is shown as a
solid line. RI, EcoRI site. Arrows beneath the lacZ reporter-neo
selection cassette show the transcriptional directions. (b) Geno-
type analysis of the wild-type, heterozygous, and homozygous mu-
tant mouse tail DNAs. (Top) Transmission of the targeted allele to
the progeny as determined by PCR. KO, targeted allele (739 bp);
WT, wild-type allele (958 bp). (Bottom) Southern hybridization
analysis. The EcoRI fragments of 4.5 and 1.6 kb derived from the
wild-type and targeted alleles, respectively. (c) Northern hybrid-
ization analysis of K19 mRNA in the wild-type, heterozygous, and
homozygous mice. 10 mg of the total RNA purified from the colon
(c), or small intestine (i) were loaded in each lane and probed with
a K19 cDNA probe (Ichinose et al., 1989). The arrowhead indi-
cates the size of the K19 mRNA (1.4 kb).
 
Table I. Genotype Analysis of Krt1-19 Heterozygous Intercrosses
 
Offspring genotype
Parent strains
 
1
 
/
 
11
 
/
 
22
 
/
 
2
 
Total
 
F
 
1
 
* 24 62 29 115
C57BL/6 (N
 
1
 
)
 
‡
 
18 36 10 64
C57BL/6 (N
 
2
 
)
 
‡
 
71 7 1 1 3 5
FBV/N (N
 
1
 
)
 
‡
 
25 28 6 59
FBV/N (N
 
2
 
)
 
‡
 
14 35 8 57
 
Numbers indicate pups from each set of intercrosses.
*Heterozygous crosses between parents in the C57BL/6 and 129/Sv backgrounds.
 
‡
 
N
 
1
 
 and N
 
2
 
 indicate the backcross numbers of the parents. 
Figure 2. Immunofluores-
cence staining of K19, K8,
K18, and K7 in the K19 gene
heterozygous and homozy-
gous mutant mouse intes-
tines. Frozen sections of the
adult mice were fixed with
methanol and stained with
TROMA-3 (anti–K19), -1
(anti–K8), and -2 (anti–K18),
and an anti–K7 mAb. 
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abolished the K19 mRNA in the small intestine and colon.
The levels of the mRNAs for K8 that complexes with K19,
and for K18, another type-I cytokeratin, were essentially un-
affected in both heterozygous and homozygous mutants
(data not shown). As expected, no K19 protein was detected
in the homozygous tissues by Western immunoblot analysis
with specific antibody TROMA-3 (data not shown). As
shown in Fig. 2, immunofluorescence stainings of the intesti-
nal sections demonstrated no K19 filaments in the homozy-
gous tissues, whereas expression of K8, K18, and K7 pro-
teins remained unaffected. It is worth noting that the K7
staining was observed in goblet cells in both genotypes.
 
Expression of K19 in Heterozygous Mutants 
Determined by 
 
b
 
-Galactosidase Expression
 
To monitor K19 expression in various tissues, the targeting
vector was designed so that a 
 
lacZ
 
 reporter gene was
driven by the 
 
Krt1-19
 
 promoter of the knocked-out allele.
We determined the 
 
b
 
-galactosidase reporter activity by
whole mount in situ staining of various organs and em-
bryos. As expected, simple epithelia of the small intestine,
cecum, and colon were stained. In the intestines, not only
the villus epithelium, but also the crypts were stained. The
squamous epithelium of the esophagus, the hair folli-
cle cells, and some gland cells in the skin also ex-
 
pressed 
 
b
 
-galactosidase (data not shown). These results
are consistent with the in situ mRNA analysis and immu-
nostaining data published previously (Bosch et al., 1988).
In the preimplantation embryo, the trophectoderm cells
of the blastocyst were stained only very weakly with X-gal.
In the 6.0-dpc embryos, 
 
b
 
-galactosidase was expressed
only in the ectoplacental cone. In the 7.0-dpc embryo, the
enzyme activity was detected mainly at the ectoplacental
cone (data not shown). In the late primitive streak stage,
 
b
 
-galactosidase was expressed in the embryo proper, at
the notochordal plate, and the node (Fig. 3, a and b).
Shortly after (7.5–8.5 dpc), an arch-shaped staining ap-
peared in the posterior embryo (Fig. 3 c). The diameter of
this arch became smaller thereafter and the staining was
localized in the hindgut pocket. When the foregut and
hindgut invaginations were formed, the endodermal cells
lining them expressed 
 
b
 
-galactosidase (Fig. 3, d and e).
Later (9.0–9.5 dpc), 
 
b
 
-galactosidase expression was limited
to the primitive gut and the notochord (Fig. 3, f–h). In
vivo, cytokeratins are not stable unless type I and type II
polypeptides are copolymerized (Kulesh et al., 1989). To
confirm the expression patterns monitored by the b-galac-
tosidase activity, the K19 mRNA and protein were ana-
lyzed in the embryos. Expression of the endogenous Krt1-
19 gene essentially corresponded to the b-galactosidase
Figure 3. Expression of the b-galactosidase gene (Krt1-19-lacZ) in the heterozygous mouse embryos at 7.5–9.0 dpc. (a and b) A repre-
sentative embryo at 7.5 dpc in the anterior and posterior views, respectively. Note the b-galactosidase activity in the notochordal plate,
node, and ectoplacental cone. (c) A representative embryo at 8.5 dpc in the posterior view. Note the b-galactosidase activity in an arch
pattern (arrows). (d and e) Another embryo at 8.5 dpc in the anterior (d) and posterior (e) views. Note that this embryo is more pro-
gressed in development than that in c: the arch pattern of the b-galactosidase staining at the hindgut (e, arrows) is much smaller than
that seen in the embryo shown in c. Also note the staining inside the foregut in d (arrow). (f and g) A representative embryo at 9.0 dpc.
(h) A transverse section of the same embryo shown in f and g (Eosin counterstaining). hf, head fold; nc, notochordal plate; nd, node; pg,
primitive gut. All dissection micrographs (whole mount in situ staining) were taken under a dark-field illumination, except a and g,
which were in a bright field. Bar, 100 mm.Tamai et al. Cytokeratins 8 and 19 in Placental Development 567
activity, although there were subtle differences in the sig-
nal intensities (data not shown).
Compound Homozygotes for K8 (Krt2-8) and 
K19 (Krt1-19) Mutations
To determine the expression patterns of K8 and K19, B6
embryos (6.5–7.5 dpc) were analyzed by immunohis-
tochemistry with TROMA-1 (anti–K8) and TROMA-3
(anti–K19), respectively. As a result, both K8 and K19 pro-
teins turned out to be expressed mostly in the extraembry-
onic tissues, in almost identical patterns. At 6.5 dpc, both
K8 and K19 were expressed mainly in the ectoplacental
cone and trophoblasts, although the level of K19 was lower
than that of K8 (data not shown). These staining patterns
were more obvious and stronger at 7.5 dpc. In addition to
ectoplacental cone and giant trophoblasts, glycogen cells,
parietal and visceral endoderm cells expressed both K8
and K19 at similar levels (Fig. 4, a–d). On the other hand,
Kip2, a marker for the ectoplacental cone and trophoblas-
tic giant cells (Riley et al., 1998), was expressed in the nu-
clei of these cells, as expected (Fig. 4, e and f). Accord-
ingly, compound homozygous mutants were constructed in
the FVB/N background to determine whether K8 and K19
have compensatory functions in vivo. The FVB/N back-
ground was chosen because more than half of the K8 gene
(Krt2-8) homozygotes survive to adults in the FVB/N
background (Baribault et al., 1994), although the homozy-
gous null mutation in the B6 background causes an embry-
onic lethality around 12 dpc (Baribault et al., 1993). First,
the F1 mice from the respective homozygous parents were
obtained. These compound heterozygotes [Krt2-8 (1/2):
Krt1-19 (1/2)] were viable and fertile. When they were in-
tercrossed, however, no compound homozygous pups
[Krt2-8 (2/2):Krt1-19 (2/2)] were found, although [Krt2-8
(1/2):Krt1-19 (2/2)] and [Krt2-8 (2/2):Krt1-19 (1/2)]
were viable and fertile (data not shown). To determine the
stage when the compound homozygous embryos became
lethal, the concepti were examined chronologically from
the intercrosses of mice that were heterozygous for the K8
Figure 4. Colocalization of K8 and
K19 in the mouse extra embryonic tis-
sues. Immunohistochemical staining
of the wild-type embryos in utero at
7.5 dpc with TROMA-3 (anti–K19),
TROMA-1 (anti–K8), and anti–Kip2
antibodies. Note that K19 and K8 are
expressed in the cytoplasm, whereas
Kip2 is in the nucleus. (a and b) Stain-
ing for K19. (c and d) Staining for K8.
(e and f) Staining for Kip2. epc, ec-
toplacental cone; gc, giant cells; glc,
glycogen cells; pe, parietal yolk sac en-
doderm; ve, visceral yolk sac endo-
derm. Note that a, c, and e are serial
sections, while b, d, and f are a higher
magnification of the sections in a, c,
and e, respectively, Bars: a, c, and e,
100 mm; b, d, and f, 50 mm.
Table II. Genotype Analysis of Compound Knockout Crosses
F1 genotypes
Krt2-8 (1/1):
Krt1-19 (2/2)
Krt2-8 (1/2):
Krt1-19 (2/2)
Krt2-8 (2/2):
Krt1-19 (2/2)
Necrotic or
resorption
7.5–9.5 dpc 24 34 18 1
10.5 dpc 14 27 4* 7
11.5–13.0 dpc 5 13 0 9
Postnatal 79 140 0 —
Parents: K8 (Krt2-8, 1/2):K19 (Krt1-19, 2/2) 3 K8 (Krt2-8, 1/2):K19 (Krt1-19,
2/2). Parents were after the sixth backcross generation into the FVB/N background.
*Embryos with abnormal morphology.The Journal of Cell Biology, Volume 151, 2000 568
mutation, but homozygous for K19 [Krt2-8 (1/2):Krt1-19
(2/2)] (Table II). DNA extracted from fetal membranes
or portions of embryos were used for genotyping. As a re-
sult, the embryos from 7.5–9.25 dpc showed the Mendelian
distribution, and no difference was observed among the
[Krt2-8 (1/1):Krt1-19 (2/2)], [Krt2-8 (1/2):Krt1-19 (2/
2)], and [Krt2-8 (2/2):Krt1-19 (2/2)] embryos. After 9.5
dpc, however, the number of the compound homozygous
embryos decreased gradually, with increasing numbers of
necrotic remnants and resorption sites. At 9.75–10.5 dpc,
some of the compound homozygous embryos were still
alive, but they were easily distinguishable by the smaller
size of their embryo-derived portion of the placenta and
varying degrees of growth retardation compared with their
littermates (Fig. 5).
The most prominent characteristic under a dissection
microscope was much more blood at the implantation
sites. Histological examination of serial sections of the tro-
phoblastic tissues at 10.5 dpc revealed lesions filled with
unnucleated maternal erythrocytes in the placenta of the
compound homozygous embryos (Fig. 6, a, c, and e com-
pared with b, d, and f, respectively). Upon closer examina-
tion at higher magnifications, the lesions also contained
some large and nucleated embryonic erythrocytes as well
(e.g., Fig. 6 g, arrows). Compared with the [Krt2-8 (1/2):
Krt1-19(2/2)] or [Krt2-8 (1/1):Krt1-19 (2/2)] concepti,
the placentas of the compound homozygotes contained
multiple layers of giant cells without the normal architec-
ture of the labyrinthine trophoblasts or spongiotropho-
blasts. The allantois was also formed very poorly (Fig. 6,
compare g with h).
To verify the histological findings at 10.5 dpc, and to in-
vestigate earlier changes in the compound homozygous
placenta, we then investigated the tissues at 9.5 dpc. A tro-
phoblast differentiation marker Kip2 was expressed in the
ectoplacental cone, trophoblast giant cells, and diploid tro-
phoblastic cells in the wild-type embryos (Fig. 4, e and f).
An immunohistochemical analysis in the compound ho-
mozygous placenta showed a marked increase in the num-
ber of the secondary giant cells already at 9.5 dpc (Fig. 7, a,
c, and e compared with b, d and f, respectively). Moreover,
these giant trophoblasts were with much larger cell bodies
and nuclei, and they were pulled apart but not tightly at-
tached to each other as in the simple K19 homozygotes. In
contrast, the number of the labyrinthine trophoblast and
spongiotrophoblast cells were decreased in cell number,
and they were poorly organized. This apparently caused
flooding of maternal blood directly into the embryonic tis-
sues where these trophoblasts normally separate embry-
onic blood from the maternal circulation. Therefore, this
Figure 5. Smaller placentas and em-
bryo growth retardation in the K8/K19
compound homozygous mutant con-
cepti. (a) A Krt2-8 (2/2):Krt1-19 (2/2)
conceptus at 9.75 dpc. Note a red le-
sion (arrowhead). (b) A Krt2-8 (2/2):
Krt1-19 (2/2) embryo, showing a re-
tarded growth. (c) A Krt2-8 ( 1/1):
Krt1-19 ( 2/2) conceptus at 9.75 dpc.
Arrow indicates the implantation site.
(d) A Krt2-8 (1/1):Krt1-19 (2/2) em-
bryo as a control. Note that a and c,
and b and d, were photographed at the
same magnifications. (e) Comparison
of the placenta between a K8/K19 com-
pound homozygote and a simple K19
homozygote, stained for b-galactosi-
dase at 9.75 dpc. (2/2,2/2) Com-
pound homozygote [i.e., Krt2-8 (2/2):
Krt1-19 ( 2/2)]; (1/1,2/2) simple
K19 homozygote [Krt2-8 ( 1/1):Krt1-
19 (2/2)]. (f) A higher magnification
of the compound homozygous concep-
tus in e.Tamai et al. Cytokeratins 8 and 19 in Placental Development 569
lesion was not hemorrhaged as shown by lack of overt
clotting (i.e, fibrin network formation), but there was in-
termixing of the maternal blood with the embryonic blood
in the placenta due to the inability of the placenta to keep
the circulation systems separate. The embryonic placenta,
including the vascular structures, was also deteriorated,
and the maternal and embryonic blood cells showed signs
of degeneration by 10.5 dpc (data not shown).
On the other hand, staining for another type II cytokera-
tin K7 in the compound homozygous placenta showed a
Figure 6. Comparison of the
placental regions at 10.5 dpc
between the K8/K19 com-
pound homozygotes and sim-
ple K19 homozygotes. (Left)
Sections from the K8/K19
compound homozygous con-
cepti [Krt2-8 ( 2/2):Krt1-19
(2/2)]. (Right) Sections
from the simple K19 homozy-
gous concepti [Krt2-8 (1/1):
Krt1-19 (2/2)]. (Stained for
b-galactosidase with he-
matoxylin counterstaining.)
Note the lesion with the ma-
ternal blood (*) and the de-
generated allantoic tissue
with less vascularization com-
pared with the healthy giant
cells and the spongiotropho-
blasts in b, d, f and h. In the
normal placenta, b-galactosi-
dase (K19) was expressed in
the giant cells and the spon-
giotrophoblasts, but not in
the allantois or the labyrin-
thine trophoblasts. Note the
degeneration in the spon-
giotrophoblasts and the laby-
rinthine trophoblasts in the
compound homozygotes. Ar-
rows in g indicate nucleated
embryonic erythrocytes. al,
allantois; e, embryonic blood;
gc, giant cells; lb, labyrinthine
trophoblast; m, maternal
blood; sp, spongiotropho-
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much weaker immunofluorescence than in the simple K19
homozygotes, and was found essentially in the tropho-
blasts, but not in the allantoic cells. At a higher magnifica-
tion, the distribution of K7 in the compound homozygotes
was more diffuse than in the K19 homozygotes (Fig. 7, g
compared with h). At the same time, a very weak K18
staining was observed in the K8 (2/2)/K19 (2/2) placenta
(data not shown). Additional experiments will be needed
to confirm the residual K18 and its presumptive partner,
which may be K7 or an additional keratin (see Discussion).
Discussion
Our results suggest that the K19 promoter is active in the
gut epithelium both in embryos and adults. At z8.0 dpc,
b-galactosidase was expressed in an arch pattern in the
posterior embryo. And this expression was soon restricted
to the inner wall of the hindgut pocket. If K19 is expressed
in the stem cells of the endoderm, this arch-shaped cluster
of cells is likely to be the precursor of the hindgut endo-
derm. Use of the K19 expression as a marker may help un-
Figure 7. Degeneration of the placenta
in the K8/19 compound homozygous
concepti at 9.5 dpc; comparison with
the K19 homozygous controls. (a–f)
Double staining with X-gal for the
b-galactosidase activity (greenish blue),
and with a specific antibody for Kip2
(brown), followed by a light counter-
staining with hematoxylin. Note that
the greenish tinge of the blue color for
X-gal is due to an electronic enhance-
ment; and that Kip2 is expressed in the
nuclei. *The placental lesion; al, allan-
tois; gc, giant cells; lb, labyrinthine tro-
phoblast; and sp, spongiotrophoblast.
(g and h) Staining for K7 by indirect
immunofluorescence microscopy. Note
that image g was electronically en-
hanced more than h. (Left) Samples of
the K8/K19 compound homozygotes
[Krt2-8 (2/2):Krt1-19 (2/2)]. (Right)
Samples of the simple K19 homozy-
gotes [Krt2-8 ( 1/1):Krt1-19 ( 2/2)].
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derstand the gut differentiation and development in embryos
and adults. Taking advantage of this finding, we recently
constructed a gene knockin mouse strain in which a bacte-
riophage P1-derived recombinase gene cre was placed un-
der the control of the K19 gene promoter (Krt1-19cre). This
mouse strain has turned out to be very useful in introduc-
ing conditional mutations in a gut-specific manner, because
a floxed b-catenin–stabilizing mutation caused thousands
of polyps in the intestines of the offspring when crossed
with the Krt1-19cre mice (Harada et al., 1999).
Type I cytokeratins, K18 and K19 can copolymerize with
type II cytokeratins such as K8 and/or K7. Our results sug-
gest that depletion of K19 per se does not interfere with
embryonic development or postnatal life in the mouse,
even though K19 is expressed at substantial levels in the
developing embryo and in the adult. Given the evolution-
ary conservation of K19 across the vertebrates, it is reason-
able to assume that K19 plays an important role that con-
fers a selective advantage. It remains to be investigated
whether K19 null mice show changes in such characteris-
tics as tumor development or wound healing. Defects may
become apparent in the K19 null mice when they are ex-
posed to a less-protected environment rather than labora-
tory conditions. The absence of an overt phenotype may be
due to compensatory functions of K18, which is coex-
pressed in the extraembryonic tissues, and K20, which is
also coexpressed in the intestine (Moll et al., 1990; Calnek
and Quaroni, 1993). If K19 and K8 contribute to the same
function, the two mutant alleles should interact genetically.
Our results confirmed this prediction: the compound ho-
mozygous embryos have a more severe phenotype than
embryos deficient in only one of the two genes. In the
FVB/N background, .50% of the homozygous K8 null
embryos survive to adulthood (Baribault et al., 1993).
However, no compound homozygotes were found among
.200 newborn pups. This result indicates a marked in-
crease in the penetrance of the lethal phenotype to 100%
in the compound homozygotes, possibly at an earlier stage
than K8 homozygotes. The compound homozygous em-
bryos have defects in the placenta, the major site of gas and
metabolite exchanges between the maternal and fetal
blood. The mouse placenta consists of three morphologi-
cally distinct trophoblast layers; namely, the labyrinthine
trophoblast, spongiotrophoblast, and giant cell layers
(Rossant, 1995; Rossant and Croy, 1985). In the compound
homozygous placenta, giant trophoblasts were increased in
number, whereas the spongiotrophoblasts and labyrinthine
trophoblasts were decreased. Failure to properly form the
chorioallantoic placenta results in embryonic lethality at
midgestation (Cross et al., 1994; Copp, 1995). Recent gene
knockout results show that the placental development is
controlled by such genes as basic helix-loop-helix tran-
scription factors Mash2 (Guillemot et al., 1994) and Hand1
(Riley et al., 1998), orphan nuclear receptor Errb (Luo et
al., 1997), and Ets2 (Yamamoto et al., 1998). In FVB/N K8
knockout mice that escape embryonic lethality, partial
hepatectomy results in gross structural alterations and ex-
planted hepatocyte death (Loranger et al., 1997). This may
reflect hypersensitivity to tumor necrosis factor (TNF),
which is moderated by K8 and K18 (Caulin et al., 2000).
The primary cause of early embryonic lethality of K8 ho-
mozygous mutants is likely due to placental malfunction
because, in the B6 background, K8-deficient embryos are
rescued by aggregation with tetraploid embryos (Kupri-
yanov and Baribault, 1998; Baribault, unpublished results).
This leads to an intriguing consideration that TNF family
cytokines may be involved in the placental abnormalities
of both B6 K8-deficient embryos and the FVB/N com-
pound homozygotes described here, because TNF is impli-
cated in trophoblast function (Rasmussen et al., 1999).
Our results indicate that compound K8 and K19 ho-
mozygous mutants, in a permissive genetic background for
K8 homozygotes, are defective in the development of pla-
cental tissues. K8 deficiency results in the complete loss of
both K18 and K19 filaments in the liver and yolk sac (Bar-
ibault and Oshima, 1991; Baribault et al., 1993). Why is the
phenotype of the compound homozygotes more severe
than the simple K8 homozygotes? Perhaps K8 is not the
only type II keratin functional in the midgestational pla-
centa. Indeed, low levels of K7 are detectable in embry-
onic placenta in addition to K18 and K19 (Fig. 7). The re-
moval of K8 results in the degradation of K18 and most
K19. However, the residual K19 that is polymerized with
K7 would remain in the K8 homozygotes, whereas K19 is
also removed in the compound homozygotes. The residual
weak signal for K7 in the compound homozygotes may be
due to K7/K8 heteropolymers.
It is worth noting that K18 null mice are viable, fertile,
and show a normal life span. This may be due to compen-
sation by K19. Old K18 null mice, however, develop a dis-
tinctive liver pathology with abnormal hepatocytes con-
taining K8 aggregates (Mallory bodies). Additionally, in
the K18 null mice, K7 was absent or markedly reduced in
the uterus, where K7, 8, 18, and 19 are to be coexpressed.
This observation indicates that cytokeratins have distinct
assembly characteristics particular to the specific tissues
(Magin et al., 1998).
In conclusion, we have constructed a K19 gene knock-
out mouse strain, the homozygotes of which were viable,
fertile, and appeared normal. When the mutation was in-
troduced into a viable K8 gene knockout mouse strain,
however, the compound homozygous embryos died in
utero due to defects in the placenta. These results indicate
that K19 and K8 cooperate in ensuring the normal devel-
opment of placental tissues.
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